Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Lomecel-B Effects on Alzheimer's Disease
- Conditions
- Mild Alzheimer's Disease
- Interventions
- Other: PlaceboDrug: Allogeneic MSC
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Longeveron Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05233774
- Locations
- 🇺🇸
Visionary Investigators Network, Aventura, Florida, United States
🇺🇸Brain Matters Research, Stuart, Florida, United States
🇺🇸Science Connections - Research Partner Group Multispecialty Group, Doral, Florida, United States
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
- Conditions
- Hypoplastic Left Heart Syndrome
- Interventions
- Biological: Lomecel-B medicinal signaling cells
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Longeveron Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04925024
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)
- Conditions
- ARDS, HumanCovid19
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Longeveron Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04629105
- Locations
- 🇺🇸
Miami VA Healthcare System, Miami, Florida, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)
- Conditions
- HLHS
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Longeveron Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03525418
- Locations
- 🇺🇸
Emory University/Childen's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University Hospital, Baltimore, Maryland, United States
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
- Conditions
- Aging Frailty
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Longeveron Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT03169231
- Locations
- 🇺🇸
Soffer Health Institute, Aventura, Florida, United States
🇺🇸Clinical Research of South Florida, Coral Gables, Florida, United States
🇺🇸Clinical Physiology Associates, Fort Myers, Florida, United States
- Prev
- 1
- 2
- Next
News
Longeveron Appoints Than Powell as Chief Business Officer to Lead Alzheimer's and HLHS Program Strategy
Longeveron Inc. has appointed Than Powell as Chief Business Officer effective July 7, 2025, to oversee partnering efforts for Alzheimer's disease and international strategy for hypoplastic left heart syndrome programs.
Longeveron's Laromestrocel Shows Promise in Phase 2a Trial for Mild Alzheimer's Disease
Longeveron's Phase 2a CLEAR MIND trial demonstrated that laromestrocel (formerly Lomecel-B) is safe and well-tolerated in patients with mild Alzheimer's disease, with no reported cases of amyloid-related imaging abnormalities.
Longeveron's Lomecel-B Nears Full Enrollment in Pivotal HLHS Trial, Shows Promise in Pediatric Heart Disease
Longeveron's Phase 2b ELPIS II trial for Lomecel-B in Hypoplastic Left Heart Syndrome has reached 90% enrollment, with completion expected in Q2 2025 and potential BLA submission in 2026.
Longeveron's Lomecel-B Shows Promise in HLHS and Alzheimer's Disease Trials
Longeveron's ELPIS II trial for HLHS, evaluating Lomecel-B™, has surpassed 80% enrollment and is deemed pivotal by the FDA for BLA submission.
Longeveron's Lomecel-B Shows Promise in Mild Alzheimer's Disease by Targeting MMP14
Longeveron presented data at CTAD24 showing Lomecel-B's potential in treating mild Alzheimer's by inhibiting MMP14, offering mechanistic and clinical insights.
Longeveron's Lomecel-B Shows Long-Term Survival Benefit in HLHS Patients
Longeveron presented data showing 100% five-year transplant-free survival in HLHS patients treated with Lomecel-B in the ELPIS I study, following Glenn surgery.
Longeveron's Lomecel-B Shows Long-Term Survival Benefit in HLHS Patients
Lomecel-B demonstrated 100% five-year transplant-free survival in HLHS patients post-Glenn surgery in the ELPIS I follow-up study, compared to 83% in the SVR trial.
Longeveron's Lomecel-B Data in Alzheimer's Disease to be Presented at CTAD24
Longeveron's Lomecel-B data, focusing on MMP14 inhibition, will be presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24).
Longeveron's Lomecel-B Shows Promising 5-Year Transplant-Free Survival in HLHS Patients
Longeveron's Lomecel-B demonstrates improved long-term transplant-free survival in infants with Hypoplastic Left Heart Syndrome (HLHS) over five years.
Cell and Gene Therapies Emerge as Promising Avenues for Alzheimer's Disease Treatment
• Several cell and gene therapies are under investigation for Alzheimer's disease, with some showing early signs of efficacy in clinical trials. • NKGen's SNK01, an autologous NK cell therapy, demonstrated encouraging clinical activity and tolerability in a Phase 1 trial, with improvements in ADCOMS scores and CSF α-syn levels. • Longeveron's Lomecel-B, an allogeneic MSC therapy, showed statistically significant improvements in ADCS-ADL scores and trends of improvement on MMSE in a Phase 2 trial. • Beyond amyloid-targeting antibodies, researchers are exploring diverse targets like tau, inflammation, and viral proteins, with drug repurposing strategies also gaining traction.